ENSC Total Utang marang Modal Ensysce Biosciences

Ensysce Biosciences (ENSC) is managed by specialized biopharmaceutical defense experts who maintain transparent relationships with regulatory authorities. The innovative TAAP platform attracts institutional investors and FDA grants, while the debt-to-equity ratio on GURU.Markets, according to the current price action shown on the chart, stands at 0.00. The company is creating a safe pain management environment by implementing overdose prevention mechanisms to combat the opioid crisis.

This ratio determines the volume of borrowed funds per unit of equity, allowing investors to assess financial leverage and bankruptcy risk amid rising rates. When analyzing the debt-to-equity ratio dynamics on GURU.Markets, it should be noted that for Ensysce Biosciences (ENSC), controlling the debt load is critical while financing the expansion of TAAP technology and conducting costly PF614 clinical trials.